Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesDividends payablesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Envoy Medical (COCH) Total Non-Current Liabilities (2022 - 2025)

Envoy Medical's Total Non-Current Liabilities history spans 4 years, with the latest figure at $20.3 million for Q4 2025.

  • Quarterly results put Total Non-Current Liabilities at $20.3 million for Q4 2025, down 31.16% from a year ago — trailing twelve months through Dec 2025 was $20.3 million (down 31.16% YoY), and the annual figure for FY2025 was $20.3 million, down 31.16%.
  • Total Non-Current Liabilities for Q4 2025 was $20.3 million at Envoy Medical, up from $14.8 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $39.7 million in Q2 2025 to a low of $4.8 million in Q4 2022.
  • The 4-year median for Total Non-Current Liabilities is $18.8 million (2024), against an average of $20.2 million.
  • The sharpest move saw Total Non-Current Liabilities soared 262.99% in 2024, then plummeted 43.0% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $4.8 million in 2022, then surged by 69.99% to $8.1 million in 2023, then soared by 262.99% to $29.5 million in 2024, then crashed by 31.16% to $20.3 million in 2025.
  • According to Business Quant data, Total Non-Current Liabilities over the past three periods came in at $20.3 million, $14.8 million, and $39.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.